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Abstract
Objective: To assess the availability and affordability of medicines and routine tests for cardiovascular disease (CVD) and
diabetes in the West region of Cameroon, a low-income setting.
Methods: A survey was conducted on the availability and cost of twelve routine tests and twenty medicines for CVD and
diabetes in eight health districts (four urban and four rural) covering over 60% of the population of the region (1.8 million).
We analyzed the percentage of tests and medicines available, the median price against the international reference price
(median price ratio) for the medicines, and affordability in terms of the number of days’ wages it would cost the lowest-paid
unskilled government worker for initial investigation tests and procurement for one month of treatment.
Results: The availability of tests varied between 10% for the ECG to 100% for the fasting blood sugar. The average cost for
the initial investigation using the minimum tests cost 29.76 days’ wages. The availability of medicines varied from 36.4% to
59.1% in urban and from 9.1% to 50% in rural settings. Only metformin and benzathine-benzylpenicilline had a median price
ratio of #1.5, with statins being largely unaffordable (at least 30.51 days’ wages). One month of combination treatment for
coronary heart disease costs at least 40.87 days’ wages.
Conclusion: The investigation and management of patients with medium-to-high cardiovascular risk remains largely
unavailable and unaffordable in this setting. An effective non-communicable disease program should lay emphasis on
primary prevention, and improve affordable access to essential medicines in public outlets.
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Introduction
Hypertension, diabetes and consequential cardiovascular dis-
eases (CVD), have reached epidemic proportions worldwide, and
disproportionately affect low- and middle-income countries
(LMICs) [1]. Nearly 80% of deaths from CVD and diabetes
occur in LMICs, resulting in non-communicable diseases (NCDs)
overtaking communicable diseases as the major leading cause of
disease and death in LMICs [1]. Moreover, the economic and
societal impact of CVD on individuals, households and countries is
enormous. These effects are particularly important in LMICs,
where CVD more often affects individuals in their working age,
and therefore contributes disproportionately to losses of potential
years of healthy and active life, which can impair economic growth
[2–4]. Indeed, it has been demonstrated that through their
combined impact on economies, health systems, households and
families, diabetes and CVD are major threats to the current and
future economic development and prosperity of individuals and
societies in Africa [5].
Timely interventions including early detection, lifestyle changes
and use of effective and affordable medicines, have been shown to
reduce morbidity and mortality associated to CVD [6]. Unfortu-
nately, studies have shown that these essential interventions for
CVD and diabetes are not always available and accessible in the
public sector in LMICs [7,8]. Although there is a better availability
of these interventions including medicines for CVD and diabetes
in the private sector, the end-user cost is a major deterrent to
access to the large segment of the population in LMICs.
Moreover, because prevention and treatment interventions for
CVD and diabetes are mostly purchased through out-of-pocket
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payments in LMIC, treatment for NCDs is largely unaffordable in
these settings [4,9].
In Cameroon where more than 50% of the population live
below the poverty line and where there is no effective health
insurance system [10,11], out-of-pocket payments represented
94.5% of private health expenditures in 2011 [12]. CVD and
diabetes are growing public health concerns in Cameroon [13].
Major deficiencies exist in both the quality and access to care such
that these NCDs and their risk factors are diagnosed infrequently
and managed inadequately. Interestingly however, CVD and
diabetes are increasingly receiving more from the Cameroon
government [13]. Since 2001, a number of health policies on
NCDs including CVD and diabetes have been formulated and
adopted by the National Ministry of Public Health. The
recognition of hypertension and diabetes as emerging public
health threats has led to the creation of the National Diabetes-
Hypertension Control Program which aims to promote equitable
access to quality health services in order to reduce the morbidity
and mortality from these conditions [14]. To achieve this goal,
making essential medicines for CVD and diabetes available and
affordable is paramount. Therefore, data on the current access to
CVD and diabetes care are crucial for shaping and improving
strategies to combat CVD and diabetes.
In May 2003, the World Health Organization (WHO) in
collaboration with Health Action International developed a
standardized method for surveying medicine prices, availability,
affordability, and price components in LMIC [15]. Using this
standardized method, the present study aimed to assess the prices,
availability and affordability of selected routine tests and common
essential medicines for CVD and diabetes care in Cameroon.
Methods
Ethics statement
The study was approved by the Regional Office of the Ministry
of Public Health (MOH) for the West region, acting as Ethics
Committee. Signed authorization was obtained from the head of
each participating outlet, who also identified the relevant
informant. All informants interviewed in the study provided a
verbal consent to take part in the study. Verbal consent was
approved by the Ethics Committee and found to be appropriate
since this study did not involve data collection on individual
subject. The consent was documented by a tick of boxes in our
data collection log book. Each of them was individually informed
on the intended use of the data collected and the confidentially
surrounding the exploitation of the data. They were further
advised that they were under no obligation to take part in the
study, and that by accepting to respond to our questionnaire they
were consenting to take part in the study and allowing the
collected data to serve the intended purpose.
Setting
We conducted a survey in the West Region of Cameroon which,
had in 2010 a population of 1,785,285 inhabitants (9.2% of the
country’s total population), with a density of 128.5 inhabitants/
km2 (2nd most densely populated region) [16]. The region is
divided into 20 health districts, and has a total of 530 health
facilities, both public and private. Public outlets acquire medicines
from the state owned Regional Centre for the Essential Drug
Program and sell them to the public on a cost-recovery basis
following the national guidelines. Private outlets acquire medicines
from a private accredited supplier, LABOREX and sell them to
the public at prices different from those recommended by the
national guidelines.
Selection of medicine outlets
Facilities were selected based on study feasibility, whether urban
or rural and the size of the population served, with the aim of
sufficiently representing the region. We selected 6 urban and 5
rural outlets. The main hospital of the capital of the region was
included, as well as one pharmacy selected as the private outlet.
This pharmacy is a popular medicine outlet with the highest
anticipated chance of getting all the needed medicines. It served as
the reference medicine outlet. One market vendor was also
sampled in the regional capital main market to serve as a reference
outlet in the informal circuit. The remaining 3 urban and 5 rural
outlets selected were those reachable within one-day’s drive from
the capital; they were all public outlets (state administered), district
hospitals or a sub-divisional hospital. In total, there were 2 private
outlets (one in the formal sector and one in the informal circuit),
Table 1. Availability of medicines and test per site and the population served.
Survey site Area
Population served
2012 estimates
Availability of
Medicines
Availability of WHO
recommended tests
Availability of
all tests
Foumban Urban 170,571 36.4% 83.3% 91.7%
Dschang Urban 211,818 45.5% 100% 100.0%
Mifi Urban 254,123 59.1% 66.7% 58.3%
Foumbot Rural 59,223 45.5% 66.7% 50.0%
Bangourain Rural 29,694 50.0% 33.3% 25.0%
Balessinga Rural NA 18.2% 50.0% 41.7%
Penka Michel Rural 88,338 22.7% 83.3% 75.0%
Mbouda Urban 250,967 50.0% 83.3% 83.3%
Batcham Rural 90,271 9.1% 50.0% 41.7%
Salviab Urban NA 100% 16.7% NA
Marketb Urban NA 63.6% NA NA
NA: Not Applicable.
a
bFound in the Mifi health district.
doi:10.1371/journal.pone.0111812.t001
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Found in Penka-Michel health district.
and 9 public outlets. In all, the selected sites served over 60% of
the population of the region, distributed in eight health districts,
four rural and four urban (Table 1).
Selection of medicines and diagnostic tests to be
surveyed
The survey collected information on 20 medicines used to treat
CVD and diabetes. Medicines were selected in line with a previous
work by a WHO team on selected essential medicines for chronic
diseases in six low and middle-income countries [7], their potential
impact on the burden of disease and their availability in standard
formulations. The majority of these medicines are included in the
WHO model list of essential medicines [17]. Diagnostic tests for
CVD and diabetes included the minimal WHO workup, and other
tests that were considered relevant for assessment and manage-
ment of cardiovascular risk as recommended by the WHO [18].
The selection was finalized after consultation with local experts.
Data collection
Data were collected by a single trained investigator in all the
sites during a one week period in 2012, using a pre-conceived
questionnaire, based on the standardized method for surveying
medicine prices, availability, affordability, and price components
in LMICs developed by the WHO and Health Action Interna-
tional [15]. For each medicine and at each outlet, information
included the availability of any drug dosage of the cheapest form
(originator brand or generic) and the cost per tablet or vial paid by
clients. The price collected from each outlet was the price charged
directly to clients. Data on tests were equally collected on the same
checklist. These data on tests were collected in the hospitals
surveyed. In the absence of social security system in Cameroon,
medications and tests covered in the current study are paid for
essentially from out-of-pocket money.
Data analysis
This was a pilot study based on a convenient sample, and
accordingly no formal power estimation. We assessed the
availability of medicines in two ways: 1) by estimating the
percentage (%) of the 20 medicines available in each site and 2)
by estimating the percentage (%) of outlets in which any dose or
form of the medicine was found. Availability less than 30% is
considered very low and greater than 80% is considered high [19].
We similarly determined the availability of tests as the percentage
of outlets in which a test was found and the percentage of tests
found at each site. We also estimated the median price ratio
(MPR) of each medicine. This ratio compares a medicine’s median
local price to its international reference price (IRP) in the
Management Sciences for Health (MSH) 2012 Price Indicator
Guide [20]. MSH international reference prices, which are
generally offered by both not-for-profit and for-profit suppliers
to developing countries, are recommended as the most useful
standard. When no supplier prices were available, buyer prices
were used. The MPR is used to express how much greater or less
the median local medicine price is than the IRP. For example, an
MPR of 2 would mean that the local medicine price is twice the
IRP. Generally, a MPR of one or less indicates an efficient public
sector procurement system. For patients’ medicine prices, MPR #
1.5 were considered reasonable for all medicine forms (usually
higher for innovator medicines) [7].
Affordability was estimated using the median medicine prices of
public medicine outlets, or private outlet when this was not
available in the public outlet, and the salary of the lowest-paid
unskilled government worker which was 28,000 FCFA/month
(USD 53) at the time of the survey, and calculating the number of
days’ wages required to pay for investigation tests and to purchase
a one-month course of treatment. Treatments costing one day’s
wage or less (for a 30-day supply of medicine) were considered
affordable.
Results
Availability of tests and medicines
The profile of the survey sites is described in Table 1. The
availability of investigation tests is summarized in Table 2; ranging
from 10% for the ECG to 100% for fasting blood sugar. It was
markedly higher in the urban setting. Across study sites, the
availability of investigation tests ranged from 58.3% to 100% for
urban sites and 41.7% to 75% for rural sites (Table 1).
Tables 1 and 3 show the availability of medicines used to treat
cardiovascular disease and diabetes. Only 9 medicines surveyed
had availability greater than 50%. This was higher in urban
Table 2. Availability, affordability and median price of selected tests in the investigation of cardiovascular disease and diabetes.
Test Availability Median price Number of days’ wage for investigation
Rural Urban All sites Local (FCFA) US Dollar
Glycaemia 100% 100% 100% 1,250 2.38 1.34
Creatinemia 80% 100% 80% 3,000 5.72 3.21
Urea 80% 100% 80% 3,000 5.72 3.21
Total cholesterol 20% 75% 40% 3,350 6.39 3.59
HDL cholesterol 20% 75% 40% 3,350 6.39 3.59
Triglyceride 20% 75% 40% 2,850 5.43 3.05
Proteinuria 100% 100% 90% 1,000 1.91 1.07
Kaliemia 40% 100% 60% 3,000 5.72 3.21
HbA1c 0% 50% 20% 11,750 22.40 12.58
Uric acid 0% 100% 40% 3,100 5.91 3.32
Full blood count 80% 100% 80% 3,750 7.15 4.02
ECG 0% 25% 10% 10,000 19.07 10.7
doi:10.1371/journal.pone.0111812.t002
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settings except for propranolol and Methyl-penicillin which was
higher in the rural settings (Table 3). Up to 7 of the surveyed
medicines were found only in private medicine outlets. Medicines’
availability across public pharmacies in different sites ranged
between 36.4% and 59.1% in urban sites and between 9.1% and
50% in rural sites (Table 1). Medicines’ availability was higher in
the urban informal sector where up to 63.6% of the medicines
were available.
Median prices and affordability of tests and medicines
The affordability of investigation tests and treatment was
estimated as the number of days’ wages the lowest-paid
government worker would be required to pay for the initial tests
and one-month course of treatment from the public sector, and
when this is not available, from the private sector. This is
summarized in Tables 2 and 3. Of all the medicines surveyed, only
the oral antidiabetics, hydrochlorothiazide and acetylsalicylic acid
cost less than 1 day’s wage. Statins remained largely unaffordable.
Only metformin and benzathine-benzylpenicilline had an accept-
able median price ratio of 0.59 and 1.23 respectively.
Table 4 depicts the minimum estimated cost of management
and monitoring of different CVD risk profiles. The minimum
number of tests to investigate a newly diagnosed hypertensive
patient including a fasting blood sugar, cholesterol, potassium
levels, proteinuria and ECG cost 29.76 days’ wages. Risk
monitoring which comprises lipid profile, fasting blood sugar
and proteinuria cost 12.6 days’ wages. As this cumulates over the
months, 12-monthly monitoring and 6-monthly monitoring cost
1.05 days’ wages and 2.11 days’ wages. Treating a patient with
ischemic heart disease with a drug combination comprising a b-
blocker (atenolol), Angiotensin Converting Enzyme Inhibitor
(captopril), statin (simvastatin) and acetylsalicylic acid will cost at
least 41.33 days’ wage. This was largely unaffordable.
Comprehensive analysis of medicine availability and
price
Figure 1 presents the availability and price of medicines
surveyed. The availability score for each medicine is depicted on
the x-axis, while the y-axis shows the value of the number of days’
wage required to purchase a one-month course of treatment. The
figure can be divided roughly into four quadrants. The upper left
quadrant (quadrant I) contains drugs with high number of days’
wage and low availability. In the case of these medicines, heparine
and simvastatin for instance, patients face both high costs and high
difficulty in obtaining them.
The lower right quadrant (quadrant IV) contains drugs with low
number of days’ wage and high availability. Furosemide had the
highest availability (100%) and one of the lowest number of days’
wage (0.17). Acetylsalicylic acid was the most affordable medicine,
with a 0.03 day’s wage, and had an availability of 70%.
Discussion
This survey is the first of this nature in Cameroon and in a large
number of low-income countries using standard methods devel-
oped and validated by the WHO [15], and with emphasis on two
common NCDs in LMICs. We focused on what patients pay for
available tests and medicines at the end of the spectrum and thus,
did not look at markups, taxes, other distribution costs and
different drug forms or conditionings, which explained differences
in prices observed in surveys carried out in geographically diverse
sites [7,8]. We carried out the survey in a geographically limited
site. However, key aspects of availability and affordability of
essential medicines are similar to other studies and are thus,
comparable.
The investigation and management of patients with medium-to-
high cardiovascular risk remains largely unavailable and unaf-
fordable in this low income setting. The minimum recommended
tests by the WHO (blood sugar, potassium, creatinemia and
proteinuria) had a satisfactory availability of 80% or more, and
comparably between rural and urban settings. Lower availabilities
of these tests have been found in Benin and Sudan [21]. Lipid
profile had low availability, especially in rural settings, and ECG
which was seen only in few urban facilities was largely unavailable.
HbA1c, a key-test in the monitory of diabetic patients also had
very low availability, and was very unaffordable. Only two tests
(blood sugar and proteinuria) cost less than 2 days’ wages and
could therefore be considered affordable. Overall, the cost of
minimal WHO recommended tests for initial diagnosis and
Table 4. Estimated costs of managing cardiovascular risk profile.
Purpose Components
Cost of tests
(days’ wages)
Costs of drugs
(days’ wages)
Total cost
(days’ wages)
Diagnosis and
stratification
Absolute
risk
Minimal WHO recommended tests 29.76 NA 29.76
Primary
prevention
,10% Risk Lifestyle changes and 12-monthly risk monitoring 1.05 NA 1.05
10220%
Risk
Lifestyle changes and 6-monthly risk monitoring 2.11 NA 2.11
20230%
Risk
Statin/Antihypertensive/6-monthly risk monitoring 2.11 30.67 32.78
$30%
Risk
Statin/Antihypertensive/Acetylsalicylic acid/3-monthly
risk monitoring
4.22 30.70 34.92
Secondary
prevention
b-Blocker, ACEI, Statin, Acetylsalicylic acid/3-monthly
risk monitoring
4.22 37.11 41.33
Minimal WHO recommended tests include fasting blood sugar, cholesterol, potassium levels, proteinuria and ECG.
Risk monitoring includes lipid profile, fasting blood sugar and proteinuria. It cost 12.6 days’ wages. As this cumulates over the months, 12-monthly monitoring and 6-
monthly monitoring cost 1.05 days’ wages and 2.11 days’ wages.
NA: not applicable.
WHO: World Health Organization; ACEI: Angiotensin Converting Enzyme Inhibitor.
doi:10.1371/journal.pone.0111812.t004
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cardiovascular risk stratification was very unaffordable, represent-
ing one month salary for the lowest-paid unskilled government
worker.
The availability of medicines in our study, although higher than
that reported in six LMICs [7], was not always optimal, therefore
indicating the existing scope of improvement. The lessons learned
from the HIV/antiretroviral experience could be applied in order
to improve access to essential medicines for NCDs [22,23]. A
recent study evaluating the preparedness of a representative
sample of 24 public and not-for-profit Tanzanian health facilities
to provide routine care for hypertension and diabetes, has shown
that compared with care for HIV, health facilities at all levels were
ill-prepared to address the diagnosis, treatment, and ongoing
monitoring needs of patients with NCDs. These results suggest
that primary-care system for HIV could serve as both model and
foundation to improve CVDs and diabetes care including access to
essential medicines [24]. Practically, to improve the availability of
essentials medicines for CVDs and diabetes in LMICs like
Cameroon, ministries of health should optimize the local
procurement practices and organize an efficient supply chain all
over the country [22]. To assure a continuous availability of these
medicines, good monitoring systems for stock levels and use are
crucial. The use of wireless communication technologies, such as
short message service (SMS), has been shown to increase
procurement efficiency and monitoring. Community volunteers
can track the availability of medicines in local facilities, and their
SMS messages can feed into a website that helps to identify
underperforming districts and start corrective action [22,23].
Figure 1. Comprehensive analysis of medicine availability and affordability. The availability (%) each drug is depicted on the x-axis, while
the y-axis shows the price (days’ wages).
doi:10.1371/journal.pone.0111812.g001
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Similar approaches for first-line antimalarial drugs have resulted in
a 50% decrease in facility stock-outs in a pilot project to improve
drug supply management in rural Tanzania [25].
Despite the relatively good availability of the surveyed
medicines, affordability was also very low with only six of the
surveyed medicines that cost less than a day’s wage. In a similar
recent study in China, these costs were much lower than those
found in our study: 0.1 days’ wages for captopril 25 mg, 0.3 days’
wages for metformine 500 mg, 1.4 days’ wages for nifedipine
20 mg and 6.6 days’ wages for losartan 50 mg [26]. A 1-month
course of combination therapy for the secondary prevention of
coronary heart disease cost 40.87 days’ wages in our setting
compared to 18 days’ wages in Malawi and 1.5 days’ wages in Sri
Lanka [7]. The unaffordability of most of medicines would be
majored if additional costs of consultation and diagnostic tests
were accounted for. A study among Cameroonian informal sector
workers which represent the vast majority of the active population
in the country, found that only 4.4% of them had health insurance
[11]. It has been shown that catastrophic payments and
impoverishment due to cardiovascular diseases are more common
in people with no health insurance than in those with health
insurance [27]. Scaling up the health insurance coverage of the
Cameroonian population is therefore crucial to improve access to
CVD and diabetes care. Generally, medicines on the national
essential medicines list (NEML) are the highest priority for
coverage by the health insurance program in sub-Saharan Africa
[22]. In the national health insurance system in Rwanda, for
example, members are eligible to receive NEML drugs for
outpatient treatment with a 10% copayment [28].
Policy options to improve access to affordable medicines
through cost containment and promotion of generics have been
suggested. Some which could be implemented in the Cameroo-
nian context include: involvement of reputed organizations and of
patients associations and consumers groups to raise awareness on
the benefit of good quality generics; reliable quality assurance
capacity to demonstrate the bioequivalence between generics and
originator brands; encouraging generic prescribing and influenc-
ing the patient to request for prescription of cheaper version of
medicines [29–31]. Generic substitution could lead to significant
financial savings. In France for instance, implementation of a
general generic substitution strategy saved nearly US$2 billion in
2008 alone [32]. Nonetheless, assurance of generic medicine
quality is crucial to protect the population from potentially
harmful effects or inefficient medicines and reduce waste of
resources. Because of inadequate regulation and insufficient
penalization, substandard medicines are common in developing
countries [23]. In Rwanda, 20% of hypertensive medicines
purchased on the market were of substandard content and 70%
were of insufficient stability [33].
Prices of medicines could be reduced by improving purchasing
efficiency, eliminating taxes and regulating markups. The analysis
of the MPR of the surveyed medicines shows that the local
procurement and retail system was inefficient, with most of the
MPR greater than 1.5. MPR was acceptable only for metformin
and benzathine-benzylpenicilline, and was as high as 70.81 for
losartan. Comparatively, a recent study in New Delhi, India, has
shown that procurement prices of surveyed medicines were
reasonable [34].
The present study has some limitations. First, sampling of
survey sites was not random with a risk of sampling bias. However,
for equity, strength and feasibility, we surveyed 8 health districts,
urban and rural, that served the majority of the population of the
region. Second, data on availability were collected at a particular
point in time and thus, they do not reflect fluctuations in the
availability over time. Third, our study present limited data from
the private sector. However, as medicines are usually cheaper in
the public sector [7], our study which mainly focuses on data from
the public sector present the ‘‘best case scenario’’ of the
affordability of drugs surveyed.
Conclusion
This study has provided some insight on issues relating to access
to cardiovascular and diabetes care in Cameroon. The investiga-
tion and management of patients with medium-to-high cardiovas-
cular risk remains largely unavailable and unaffordable in this low
income setting. An effective NCD program should lay emphasis on
primary prevention, and improve access to affordable generic
essential medicines in public outlets.
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